011040

KDPharm is a pharmaceutical company established in 1976 that manufactures and sells prescription and over-the-counter medicines, active pharmaceutical ingredients, and health supplements. The company's primary business segment is pharmaceuticals, which accounts for the majority of its revenue, with additional income from real estate leasing and other products. Key products include Duo Lovan tablets, Alpotin soft capsules, Durofin sustained-release tablets, and the WIAVIM health supplement brand. KDPharm serves the domestic market through hospitals, clinics, and pharmacies, with a small portion of sales exported via pharmaceutical trading companies. The company operates GMP-compliant manufacturing facilities and focuses on developing improved new drugs, generics, and complex formulations for cardiovascular, digestive, and respiratory conditions. It also engages in research and development for active ingredients such as risperidone and pitavastatin calcium hydrate, and has signed joint research agreements with partners like Incelibro.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage kdpharma.co.kr
Sector Healthcare IR page —
Tags
prescription drugs, over-the-counter drugs, active pharmaceutical ingredients, health supplements, cardiovascular drugs, digestive drugs, respiratory drugs, complex formulations, generics, improved new drugs, Duo Lovan, Alpotin, Durofin, Euro nal, Valtrio, Dapamet, WIAVIM, Kotuluten, Anico In Hot & Cool Plaster, Incilibro
Press page —

Metrics

Valuation  
Market cap ₩ 152.305B
P/E 5.95
P/BV 0.66
P/S 0.76
P/OCF 7.37
P/FCF 33.07
Dividend yield —
Turnover / mcap —
Returns  
ROE 3.8%
ROI 3.7%
ROIC 3.1%
Profit margin 4.3%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 17.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 196.273B 193.936B 162.674B 182.718B 177.611B 173.828B 176.5B 179.316B 177.772B 158.599B 151.893B 153.26B 133.074B
Free cash flow -1.46B -15.692B -6.322B -11.649B 8.496B -11.475B -4.836B 29.337B 9.044B 18.433B 7.57B 1.958B 7.041B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 5.82K 5.77K — — — — — — — — — — —
Price performance 12m 0.01 — — — — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

KDPharm (ticker 011040), listed in South Korea.